HAS-BLED estimates 1-year risk of major bleeding in patients with AF on anticoagulation. Each letter scores 1 point (maximum 9):
- H — Hypertension (uncontrolled SBP >160 mmHg): 1 pt
- A — Abnormal renal function (dialysis, transplant, SCr >2.26 mg/dL / >200 µmol/L): 1 pt | Abnormal liver function (cirrhosis, bilirubin >2×ULN, AST/ALT >3×ULN): 1 pt (max 2 total for A)
- S — Stroke history: 1 pt
- B — Bleeding history or predisposition (anemia, bleeding diathesis): 1 pt
- L — Labile INR (if on warfarin, TTR <60%): 1 pt
- E — Elderly (age >65): 1 pt
- D — Drugs (antiplatelets, NSAIDs): 1 pt | Alcohol use (≥8 drinks/week): 1 pt (max 2 total for D)
Score interpretation: 0–1 = Low risk (~1%/year); 2 = Intermediate (~2–3%/year); ≥3 = High risk (>4%/year).
Check each criterion that applies. The score and risk category update automatically. All computation runs in your browser; no values are stored or transmitted.
When to Use
Use HAS-BLED in patients with atrial fibrillation being considered for long-term anticoagulation to estimate 1-year major bleeding risk and to identify addressable risk factors.
Appropriate population
- AF patients being considered for anticoagulation
- CKD patients with AF (renal dysfunction scores +1 under A)
- Dialysis patients with AF — both renal A criteria may apply
- Annual reassessment of anticoagulation risk-benefit
Important caveat
HAS-BLED is not a tool to withhold anticoagulation. It is a tool to identify and address modifiable risk factors. Use alongside CHA₂DS₂-VASc to weigh stroke vs. bleeding risk in a shared decision-making framework.
Pearls & Pitfalls
Address modifiable factors
BP control, stopping NSAIDs/antiplatelets where safe, correcting anemia, and optimizing INR (or switching to DOAC) can each reduce the HAS-BLED score by 1 point — turning a "high risk" into "intermediate risk" while preserving stroke protection.
CKD and ESRD considerations
CKD/ESRD patients: score ≥3 is common; use HAS-BLED alongside CHA₂DS₂-VASc to guide shared decision-making. DOACs are generally preferred over warfarin in CKD (eGFR 25–49 mL/min); warfarin preferred in ESRD on dialysis per most current guidelines.
Pitfalls
- "High HAS-BLED" does NOT mean anticoagulation is contraindicated — stroke risk almost always outweighs bleeding risk when CHA₂DS₂-VASc ≥2 (males) or ≥3 (females).
- The L criterion (labile INR) does not apply if the patient is on a DOAC — skip it.
- Both renal and liver criteria count separately under A (max 2 points for A).
- Score was derived in a Western European AF cohort; local calibration may differ.
Why Use It
HAS-BLED is the most widely validated clinical bleeding risk score in AF and is endorsed by ESC, ACC/AHA, and CCS guidelines. Unlike simple contraindication checklists, it quantifies risk on a continuous scale, flags modifiable contributors, and enables a structured conversation about risk-benefit of anticoagulation. In nephrology practice, where both AF and bleeding risk are elevated in CKD/ESRD patients, HAS-BLED provides a systematic framework for shared decision-making alongside CHA₂DS₂-VASc.
- Identifies patients at higher bleeding risk who need closer monitoring
- Guides shared decision-making for anticoagulation in AF with CKD
- Helps prioritize which modifiable risk factors to address first
HAS-BLED Score
Check all criteria that apply. The score, risk category, and management guidance update automatically.
HAS-BLED Criteria (check all present)
Next Steps
Use the HAS-BLED score to guide management decisions alongside CHA₂DS₂-VASc.
- Score ≥3: Identify and address ALL modifiable risk factors; consider more frequent INR monitoring or switching DOAC over warfarin; close follow-up every 3–6 months; do not withhold anticoagulation solely based on HAS-BLED if stroke risk is high.
- Score 0–2: Proceed with anticoagulation per stroke risk (CHA₂DS₂-VASc ≥2 in males, ≥3 in females); address any risk factors identified; standard annual reassessment.
- For all scores: Address modifiable factors — BP control, stop NSAIDs where safe, correct anemia, optimize INR if on warfarin, reduce alcohol intake.
- Reassess HAS-BLED score at each clinical review; a reduction in score after optimizing modifiable factors supports continued anticoagulation.
Evidence & References
HAS-BLED Score Components
| Letter | Clinical characteristic | Points |
|---|---|---|
| H | Hypertension — uncontrolled SBP >160 mmHg | 1 |
| A | Abnormal renal function — dialysis, transplant, or SCr >2.26 mg/dL (>200 µmol/L) | 1 |
| A | Abnormal liver function — cirrhosis, bilirubin >2×ULN, or AST/ALT >3×ULN | 1 |
| S | Stroke history | 1 |
| B | Bleeding history or predisposition (anemia, bleeding diathesis) | 1 |
| L | Labile INR — if on warfarin, TTR <60% | 1 |
| E | Elderly — age >65 years | 1 |
| D | Drugs — antiplatelet agents or NSAIDs | 1 |
| D | Alcohol — ≥8 drinks/week | 1 |
| Maximum score | 9 | |
Risk Interpretation
| Score | Risk category | Estimated annual bleeding risk | Recommendation |
|---|---|---|---|
| 0–1 | Low | ~1% / year | Anticoagulation generally appropriate if stroke risk warrants |
| 2 | Intermediate | ~2–3% / year | Anticoagulate with care; address modifiable factors |
| ≥3 | High | >4% / year | Do NOT withhold anticoagulation; aggressively address all modifiable factors |
References
- Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. Chest. 2010;138(5):1093–1100. doi:10.1378/chest.10-0134.
- Lip GYH, Frison L, Halperin JL, Lane DA. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. Chest. 2010;137(2):263–272. doi:10.1378/chest.09-1584.
